|
1
|
Hastings K, Yu HA, Wei W, Sanchez-Vega F,
DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, et al:
EGFR mutation subtypes and response to immune checkpoint blockade
treatment in non-small-cell lung cancer. Ann Oncol. 30:1311–1320.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ready N, Hellmann MD, Awad MM, Otterson
GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M,
et al: First-line nivolumab plus ipilimumab in advanced
non-small-cell lung cancer (CheckMate 568): Outcome by programmed
death ligand 1 and tumor mutational burden as biomarkers. J Clin
Oncol. 37:992–1000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kagamu H, Kitano S, Yamaguchi O, Yoshimura
K, Horimoto K, Kitazawa M, Fukui K, Shiono A, Mouri A, Nishihara F,
et al: CD4+ T-cell immunity in the peripheral blood
correlates with response to anti-PD-1 therapy. Cancer Immunol Res.
8:334–344. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaira K, Yamaguchi O, Kawasaki T,
Hashimoto K, Miura Y, Shiono A, Mouri A, Imai H, Kobayashi K,
Yasuda M, et al: Prognostic significance of tumor infiltrating
lymphocytes on first–line pembrolizumab efficacy in advanced
non–small cell lung cancer. Discov Oncol. 14:62023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamaguchi O, Kaira K, Hashimoto K, Mouri
A, Shiono A, Miura Y, Murayama Y, Kobayashi K, Kagamu H and Kuji I:
Tumor metabolic volume by 18F-FDG-PET as a prognostic
predictor of first-line pembrolizumab for NSCLC patients with
PD-L1≧50. Sci Rep. 10:149902020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hashimoto K, Kaira K, Yamaguchi O, Mouri
A, Shiono A, Miura Y, Murayama Y, Kobayashi K, Kagamu H and Kuji I:
Potential of FDG-PET as prognostic significance after anti-PD-1
antibody against patients with previously treated non-small cell
lung cancer. J Clin Med. 9:7252020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaira K, Kuji I and Kagamu H: Value of
F-FDG-PET to predict PD-L1 expression and outcomes of PD-1
inhibition therapy in human cancers. Cancer Imaging. 21:112021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hashimoto K, Kaira K, Imai H, Mouri A,
Shiono A, Miura Y, Yamaguchi O, Kobayashi K, Kagamu H and Kuji I:
Prognostic potential of metabolic activity on 18 F–FDG Accumulation
in advanced NSCLC receiving combining chemotherapy plus PD–1
Blockade. J Immunother. 45:349–357. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Umeda Y, Morikawa M, Anzai M, Ameshima S,
Kadowaki M, Waseda Y, Shigemi H, Tsujikawa T, Kiyono Y, Okazawa H
and Ishizuka T: Predictive value of integrated 18F-FDG
PET/MRI in the early response to nivolumab in patients with
previously treated non-small cell lung cancer. J Immunother Cancer.
8:e0003492020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kaira K, Higuchi T, Naruse I, Arisaka Y,
Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, et al:
Metabolic activity by 18F-FDG-PET/CT is predictive of
early response after nivolumab in previously treated NSCLC. Eur J
Nucl Med Mol Imaging. 45:56–66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mahiat C, Bihin B, Duplaquet F, Stanciu
Pop C, Dupont M, Vander Borght T, Rondelet B, Vanderick J, André B,
Pirard L, et al: Systemic inflammation/nutrition status scores are
prognostic but not predictive in metastatic non-small-cell lung
cancer treated with first-line immune checkpoint inhibitors. Int J
Mol Sci. 24:36182023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Seban RD, Assie JB, Giroux-Leprieur E,
Massiani MA, Bonardel G, Chouaid C, Deleval N, Richard C, Mezquita
L, Girard N, et al: Prognostic value of inflammatory response
biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced
NSCLC patients treated with first-line chemo- or immunotherapy.
Lung Cancer. 159:45–55. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaira K, Oriuchi N, Otani Y, Yanagitani N,
Sunaga N, Hisada T, Ishizuka T, Endo K and Mori M: Diagnostic
usefulness of fluorine-18-alpha-methyltyrosine positron emission
tomography in combination with 18F-fluorodeoxyglucose in
sarcoidosis patients. Chest. 131:1019–1027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dolan RD, Maclay JD, Abbass T, Colville D,
Buali F, MacLeod N, McSorley ST, Horgan PG and McMillan DC: The
relationship between 18F-FDG-PET CT-derived tumour
metabolic activity, nutritional risk, body composition, systemic
inflammation and survival in patients with lung cancer. Sci Rep.
10:208192020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eba J and Nakamura K: Overview of the
ethical guidelines for medical and biological research involving
human subjects in Japan. Jpn J Clin Oncol. 52:539–544. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gandhi L, Rodríguez–Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et
al: Pembrolizumab plus chemotherapy for squamous non-small-cell
lung cancer. N Engl J Med. 379:2040–2051. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumour:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Imai H, Kishikawa T, Minemura H, Yamada Y,
Ibe T, Yamaguchi O, Mouri A, Hamamoto Y, Kanazawa K, Kasai T, et
al: Pretreatment Glasgow prognostic score predicts survival among
patients with high PD-L1 expression administered first-line
pembrolizumab monotherapy for non-small cell lung cancer. Cancer
Med. 10:6971–6984. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Platini H, Ferdinand E, Kohar K, Prayogo
SA, Amirah S, Komariah M and Maulana S: Neutrophil-to-Lymphocyte
ratio and Platelet-to-Lymphocyte ratio as prognostic markers for
advanced non-small-cell lung cancer treated with immunotherapy: A
systemic review and meta-analysis. Medicina (Kanuas). 58:10692022.
View Article : Google Scholar
|
|
22
|
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W,
Zhang X, Wang WM, Qiu SJ, Zhou J and Fan J: Systemic
immune-inflammation index predicts prognosis of patients after
curative resection for hepatocellular carcinoma. Clin Cancer Res.
20:6212–6222. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jafri SH, Shi R and Mills G: Advance lung
cancer inflammation index (ALI) at diagnosis is a prognostic marker
in patients with metastatic non-small cell lung cancer (NSCLC): A
retrospective review. BMC Cancer. 13:1582013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guthrie GJ, Roxburgh CS, Richards CH,
Horgan PG and McMillan DC: Circulating IL-6 concentrations link
tumour necrosis and systemic and local inflammatory responses in
patients undergoing resection for colorectal cancer. Br J Cancer.
109:131–137. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Song M, Zhang Q, Song C, Liu T, Zhang X,
Ruan G, Tang M, Xie H, Zhang H, Ge Y, et al: The advanced lung
cancer inflammation index is the optimal inflammatory biomarker of
overall survival in patients with lung cancer. J Cachexia
Sarcopenia Muscle. 13:2504–2514. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang X, Teng F, Kong L and Yu J: PD-L1
expression in human cancers and its association with clinical
ouctomes. Onco Targets Ther. 9:5023–5039. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
O'Callaghan DS, O'Donnell D, O'Connell F
and O'Byrne KJ: The role of inflammation in the pathogenesis of
non-small cell lung cancer. J Thorac Oncol. 5:2024–2036. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Diakos CI, Charless KA, McMillan DC and
Clarke SJ: Cancer-related inflammation and treatment effectiveness.
Lancet Oncol. 15:e495–503. 2014. View Article : Google Scholar
|
|
29
|
Laird BJA, Fallon M, Hjermstad MJ, Tuck S,
Kaasa S, Klepstad P and McMillan DC: Quality of life in patients
with advanced cancer: Different association with performance status
and systemic inflammatory response. J Clin Oncol. 34:2769–2775.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Suresh K, Psoter KJ, Voong KR, Shankar B,
Forde PM, Ettinger DS, Marrone KA, Kelly RJ, Hann CL, Levy B, et
al: Impact of checkpoint inhibitor pneumonitis on survival in NSCLC
patients receiving immune checkpoint immunotherapy. J Thorac Oncol.
14:494–502. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gomatou G, Tzilas V, Kotteas E, Syrigos K
and Bouros D: Immune checkpoint inhibitor-related pneumonitis.
Respiration. 99:932–942. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Minegishi Y, Takenaka K, Mizutani H, Sudoh
J, Noro R, Okano T, Azuma A, Yoshimura A, Ando M, Tsuboi E, et al:
Exacerbation of idiopathic interstitial pneumonias associated with
lung cancer therapy. Intern Med. 48:665–672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Akaike K, Saruwatari K, Oda S, Shiraishi
S, Takehashi H, Hamada S, Iyama S, Horio Y, Yusuke T, Saeki S, et
al: Predictive value of 18F-FDG PET/CT for acute
exacerbation of interstitial lung disease in patients with lung
cancer and interstitial lung disease treated with chemotherapy. Int
J Clin Oncol. 25:681–690. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kikuch R, Takoi H, Tsuji T, Nagatomo Y,
Tanake A, Kinoshita H, Ono M, Ishiwari M, Kazutoshi T, Kono Y, et
al: Glasgow prognostic score predicts chemotherapy-triggered acute
exacerbation-interstitial lung disease in patients with non-small
cell lung cancer. Thorac Cancer. 12:667–675. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Haratani K, Hayashi H, Chiba Y, Kudo K,
Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M and
Nakagawa K: Association of Immune-related adverse events with
nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol.
4:378. 2018. View Article : Google Scholar
|
